Spots Global Cancer Trial Database for Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Official Title: Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Study ID: NCT04620603

Conditions

Cutaneous Malignant Melanoma

Renal Cell Cancer

Urothelial Cancer of Renal Pelvis

Interventions

Low Dose Rate Brachytherapy (LDR)

Standard-of-Care Immunotherapy

Study Description

Brief Summary: This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.

Detailed Description: The purpose of this study is to evaluate the effect of combining LDR with immune checkpoint inhibition in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer. This involves the addition of a treatment called brachytherapy to SOC immunotherapy. Brachytherapy is a form of radiation therapy where radioactive pellets are placed within a tumor to temporarily irradiate the tumor at a low level. This is the first time that this combination (immunotherapy and brachytherapy) has been used in humans. The objectives of this study are to evaluate the effect of combining LDR with immunotherapy, determine safety and feasibility, generate a toxicity profile, evaluate response, and overall survival.